{
    "clinical_study": {
        "@rank": "90704", 
        "arm_group": [
            {
                "arm_group_label": "Ertapenem", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Faropenem\uff08low-dose group)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Faropenem\uff08high dose group\uff09", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety  and Efficacy of Faropenem  in\n      community-acquired pneumonia (CAP) subjects\uff0cand explore its therapeutic dose."
        }, 
        "brief_title": "A Phase II Study of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia", 
        "completion_date": {
            "#text": "July 2012", 
            "@type": "Actual"
        }, 
        "condition": "Community Acquired Pneumonia", 
        "condition_browse": {
            "mesh_term": [
                "Pneumonia, Bacterial", 
                "Pneumonia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients aged between 18~70 years, either male or female\n\n          2. Patients requiring hospitalization or emergency room observation, and the need to\n             receive intravenous antibiotic treatment\n\n          3. Women of childbearing age having negative pregnancy test at the time of enrollment\n             and agreeing to take effective contraceptive measures from the delivery to 7 ~14 days\n             after stopping .(for example: oral contraception, injectable contraception, or\n             implant contraception , spermicides and condoms, or intrauterine device).\n\n          4. Comply with  clinical,  radiological and microbiological criteria of\n             Community-Acquired Pneumonia(CAP):\n\n          5. Patients had used ineffective systemic antimicrobial drugs before enrollment or had\n             effective antimicrobial drugs within 72 h before enrollment, used <24 h\n\n          6. Informed consent granted\n\n        Exclusion Criteria:\n\n          1. Patients with atypical pneumonia infected by the Mycoplasma pneumoniae, Chlamydia\n             pneumoniae, Legionella pneumophila bacteria;\n\n          2. Patients infected by pathogens methicillin-resistant Staphylococcus aureus,\n             Pseudomonas aeruginosa or Acinetobacter baumanns ;\n\n          3. Viral pneumonia;\n\n          4. Aspiration pneumonia;\n\n          5. Hospital-acquired pneumonia, including ventilator-associated pneumonia;\n\n          6. Patients with Severe pneumonia who meet one primary criterion or three secondary\n             criteria (See Appendix);\n\n          7. Patients with a rapid progressive or end-stage disease, and can not survive until the\n             end of the study period by antibiotic treatment;\n\n          8. Patients with bronchial obstruction or a history of obstructive pneumonia (not\n             including chronic obstructive pulmonary disease);\n\n          9. Suffering from any of the following diseases: active tuberculosis, bronchiectasis,\n             lung abscess, lung cancer, non-infectious interstitial lung disease, pulmonary edema,\n             atelectasis, pulmonary embolism, pulmonary eosinophil infiltration disease and\n             pulmonary vasculitis;\n\n         10. Infections acquired from hospitals, nursing homes or other long-term care facilities,\n             or patients hospitalized within 14 days prior to enrollment ;\n\n         11. Allergic to penem and carbapenem antibiotic;\n\n         12. Pregnancy or lactation in women;\n\n         13. Patients with uncontrolled psychiatric history or those at risk of suicide two years\n             prior to enrollment;\n\n         14. A  history of epilepsy or other central nervous system disorders in patients;\n\n         15. Patients with Renal dysfunction, screening serum creatinine values above the upper\n             limit of normal 10%;\n\n         16. The Screening  alanine aminotransferase (ALT) or aspartate aminotransferase (AST) is\n             3 times the upper limit of the reference value, or total bilirubin beyond the upper\n             limit of the normal range by 10% ;\n\n         17. Serious diseases that affecting the immune system, such as: a human immunodeficiency\n             virus (HIV) infection history, or cluster of differentiation 4  + T-lymphocyte count\n             <200/200/mm3, or Neutrophilic granulocytopenia (neutrophil count <1500/mm3), or\n             hematologic malignancies or solid organ or splenectomy, etc;\n\n         18. Patients who are taking steroid medications, at least 20 mg daily dose of\n             prednisone(or equivalent doses of other glucocorticoids);\n\n         19. Patients who are accepting chemotherapy drug therapy or anti-cancer therapy, or plan\n             to accept such treatment during the trial six months prior to enrollment;\n\n         20. Alcohol or illicit drug abuse history;\n\n         21. Patients who have accepted any other experimental drugs within 3 months prior to\n             enrollment;\n\n         22. more than 500 ml blood donation within 3 months prior to enrollment;\n\n         23. Patients who have participated in this clinical trial ever before;\n\n         24. Combined use of other antibacterial drugs in patients;\n\n         25. Patients are diagnosed to have potential increased risks, or there may be\n             interference with clinical trials;"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "189", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01886053", 
            "org_study_id": "ZTDQ04104-CTF"
        }, 
        "intervention": [
            {
                "arm_group_label": "Faropenem\uff08high dose group\uff09", 
                "description": "dosage form: Injection dosage:2400 mg frequency: Three times a day", 
                "intervention_name": "Faropenem\uff08high dose group\uff09", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Faropenem\uff08low-dose group)", 
                "description": "dosage form: Injection  dosage:2400 mg  frequency: twice a day", 
                "intervention_name": "Faropenem\uff08low-dose group)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Ertapenem", 
                "description": "dosage form: Injection dosage:1000 mg frequency: once a day", 
                "intervention_name": "Ertapenem", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ertapenem"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "June 19, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Hefei", 
                        "country": "China", 
                        "state": "Anhui", 
                        "zip": "230001"
                    }, 
                    "name": "Anhui Provincial Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "state": "Guangdong", 
                        "zip": "510630"
                    }, 
                    "name": "The Third Affiliated Hospital of Sun Yat-sen University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "state": "Guangdong", 
                        "zip": "510080"
                    }, 
                    "name": "First Affiliated Hospital of Sun Yat-sen University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "state": "Guangdong", 
                        "zip": "510120"
                    }, 
                    "name": "Sun Yat-sen Memorial Hospital Sun Yat-sen University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shiyan", 
                        "country": "China", 
                        "state": "Hubei", 
                        "zip": "442000"
                    }, 
                    "name": "Taihe Hospital in Shiyan City"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Changchun", 
                        "country": "China", 
                        "state": "Jilin"
                    }, 
                    "name": "The Second Hospital of Jilin University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Qingdao", 
                        "country": "China", 
                        "state": "Shandong", 
                        "zip": "266000"
                    }, 
                    "name": "Qingdao Municipal Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "zip": "200040"
                    }, 
                    "name": "Huashan Hospital ,Fudan University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tianjin", 
                        "country": "China", 
                        "zip": "300211"
                    }, 
                    "name": "The Second Hospital of Tianjin Medical University"
                }
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase II Study to Evaluate the Efficacy and Safety of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Per subject clinical cure rate", 
                "safety_issue": "Yes", 
                "time_frame": "14-28 days"
            }, 
            {
                "measure": "Per subject microbiological cure rate", 
                "safety_issue": "Yes", 
                "time_frame": "14-28 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01886053"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}